A 10,000-Foot View at Survival and Treatment with Phosphodiesterase-5 Inhibitors in Interstitial Lung Disease Pulmonary Hypertension

Affiliations

¹ Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church, Virginia.
² Pulmonology Department Hospital del Mar Barcelona, Spain.

Editorial

Oksana A Shlobin et al. Am J Respir Crit Care Med. 2025 Oct.

. 2025 Oct;211(10):1749-1751.

doi: 10.1164/rccm.202508-1980ED.

¹ Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church, Virginia.
² Pulmonology Department Hospital del Mar Barcelona, Spain.

No abstract available

Figures

Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis.
Yogeswaran A, Hassoun PM, Saleh K, Fünderich M, Balasubramanian A, Konswa Z, Kiely DG, Lawrie A, Thenappan T, Eichstaedt CA, Grünig E, Wilkins MR, Howard L, Olschewski H, Kovacs G, Cajigas HR, Frantz R, Sabbour H, Sweatt AJ, Zamanian RT, Arvanitaki A, Giannakoulas G, Elwing J, Jose A, Beckmann S, Olsson KM, Stadler S, Held M, Halank M, Ewert R, Behr J, Milger-Kneidinger K, Pausch C, Pittrow D, Majeed RW, Wilhelm J, Ghofrani HA, Grimminger F, Tello K, Hoeper MM, Seeger W; PVRI-GoDeep-Consortium. Yogeswaran A, et al. Am J Respir Crit Care Med. 2025 Oct;211(10):1855-1866. doi: 10.1164/rccm.202412-2371OC. Am J Respir Crit Care Med. 2025. PMID: 40772955

1. Shlobin OA, Adir Y, Barbera JA, Cottin V, Harari S, Jutant EM. et al. Pulmonary hypertension associated with lung diseases. Eur Respir J . 2024;64:2401200. - PMC - PubMed
1. Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D. et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J . 2024;64:2401324. - PMC - PubMed
1. Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM. et al. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: a consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative—Group 3 pulmonary hypertension. Pulm Circ . 2023;13:e12213. - PMC - PubMed
1. Yogeswaran A, Hassoun PM, Saleh K, Fünderich M, Balasubramanian A, Konswa Z. et al. PVRI GoDeep Consortium. Hemodynamics and phosphodiesterase-5 inhibitor treatment associated with survival in ILD-PH: a PVRI GoDeep meta-registry analysis. Am J Respir Crit Care Med . 2025;211:1855–1866. - PubMed
1. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R. et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant . 2017;36:957–967. - PubMed